VivoSight OCT scanner is used to examine lesion on patient's nose: image via michelsondiagnostics.com For many of the 13 million Americans currently at risk for non-melanoma skin cancers, the VivoSight® Optical Coherence Tomography (OCT) scanner will be a blessing in their dermatologists' tool closet. The device, just approved for clinical use by the FDA, offers real-time laser imaging of a patient's skin, enabling better, and sometimes immediate, treatment of basal or squamous cell cancers.
The revolutionary VivoSight OCT scanner can, in a trained dermotologists' hands, obviate the need for some biopsies and, in other cases, indicate when biopsies should definitely be run. It can also be used to decide what kind of treatment should be applied and whether or not the cancer should be excised. Post treatment, the VivoSight is an invaluable tool to track treatment progress.
Here is a still image of a basal cell carcinoma 'nest,' often seen in arched tumor islands like this.
The raised mound to the right of center on this scan is identifiable as Basal cell carcinoma: ©Michelson Diagnostics
The VivoSight OCT scanner, is created by British medical device company, Michelson Diagnostics Ltd. Though the scanner was approved for use in Britain, Europe, and other countries, the VivoSight is just getting off the ground in the U.S., with one of the most well-known groups, Grammercy Park Dermatology, leading the way.
If you would like to view a basal carcinoma scan in motion, visit Michelson's image of the month here. For more still images of the skin, including cancerous lesions, via the VivoSight OCT, download the images here. If you follow the script included with the images from the beginning of the presentation, you will learn about how basal and squamous cell cancers are recognized.
sources: Market Watch, MichelsonDiagnostics Ltd., Grammercy Part Dermatology